Know Cancer

forgot password

A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

Phase 1
18 Years
Not Enrolling
Metastatic Breast Cancer, Breast Cancer

Thank you

Trial Information

A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

CT-2103 is a chemotherapy drug designed to deliver an active chemotherapy medication
(paclitaxel) inside of tumor cells. Gemcitabine is FDA approved for the treatment of breast

Before you can start receiving drug on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in the
study. You will have a complete medical history and physical exam. You will have a CT scan
of the chest and abdomen, a bone scan, and a chest x-ray performed to document the size and
location of the tumor(s). Blood (about 2 tablespoons) will be drawn for routine tests. Women
who are able to have children must have a negative blood-pregnancy test.

If you are found to be eligible to take part in this study, you will be assigned to a dose
of CT-2103. Participants in this study will be enrolled in groups of 3. The first group
will receive the lowest dose of CT-2103. Each new group of patients will receive a higher
dose until the highest safe dose is found. The dose that you receive will depend on how
many patients have received CT-2103 before you. You will only be assigned to one dose
level, and you will stay at this same dose level for the entire study unless you have a
serious side effect that requires the dose to be decreased or stopped. All participants
will receive the same dose of gemcitabine, though it too may be lowered if severe side
effects occur.

Both CT-2103 and gemcitabine are given through a vein. On the first day of your therapy
(called 'Day 1'), you will receive a routinely given medication, ondansetron (Zofran), that
will help decrease the risk of nausea. About 30 minutes later, CT-2103 will be given over
10-20 minutes followed by gemcitabine over 30 minutes.

One week later ('Day 8'), you will receive gemcitabine through the vein over about 30
minutes. You will return to see your doctor 3 weeks after your first dose of chemotherapy
('Day 21'), and then this pattern or cycle of treatment will be given again.

You will continue on therapy as long as the cancer is being controlled and you are not
having unexpected or intolerable side effects. All chemotherapy will be given at M. D.

You will have blood (about 2 tablespoons) collected once a week while you are on study to
monitor the effects of chemotherapy on your bone marrow and liver and kidney function. You
will see your doctor every 3 weeks to monitor how you are tolerating the therapy. At these
visits, your doctor will discuss any symptoms you are having, and you will have a physical
exam. If you are taking warfarin (Coumadin) you will need to have blood (about 1 tablespoon)
collected three times a week to monitor you warfarin levels.

After each 6 weeks of chemotherapy, you will have repeat scans to evaluate the effects of
the study drugs upon your cancer.

Once you have stopped taking therapy with CT-2103 and gemcitabine, you will be asked to
return to see your physician in about 6 weeks to evaluate how you are doing and to find out
if there has been any additional change in the cancer. You will have a complete medical
history and physical exam. You will have a CT scan of the chest and abdomen, a bone scan,
and a chest x-ray performed to document the size and location of the tumor(s).

This is an investigational study. Gemcitabine is FDA approved for the treatment of breast
cancer when given in combination with paclitaxel. Gemcitabine will not be provided free of
charge. CT-2103 is not yet FDA approved and will be provided free of charge during the
study. Any laboratory testing that is not standard of care will be paid for by the
supporting company. About 18 women will take part in this study. All will be enrolled at M.
D. Anderson.

Inclusion Criteria:

1. Patients must have histologically confirmed breast cancer that is either metastatic
or unresectable.

2. Patients must have received anthracyclines as treatment of either early stage or
metastatic breast cancer.

3. Previous taxane therapy is allowed.

4. Age >/= 18 years. There is limited data regarding the use of CT-2103 in children
under 18 and they will be excluded from this combination dose finding study.

5. Eastern Cooperative Oncology Group (ECOG) performance status /=

6. Measurable disease is not required.

7. Previous endocrine therapies are allowed but should be discontinued prior to
initiation of therapy.

8. Patients must sign an informed consent indicating that they are aware of the
investigational nature of the study, in keeping with institutional policy.

9. The effects of CT-2103 on the developing human fetus are unknown. For this reason
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation. Females of childbearing potential are
defined as females who have not undergone a hysterectomy or who have not been
postmenopausal for at least 24 months.

10. Patients must have normal organ and marrow function as defined below: leukocytes >/=
3,000/ul; absolute neutrophil count >/= 1,500/ul; platelets >/= 100,000/ul; total
bilirubin within normal institutional limits; aspartate aminotransferase (AST or
SGOT) and alanine aminotransferase (ALT or SGPT) of normal; creatinine within normal institutional limits or creatinine clearance >/=
60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal;
coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal
limits unless patients are already anti-coagulated for other reasons (i.e., atrial
fibrillation, etc.).

11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if
clinically appropriate.

Exclusion Criteria:

1. Patients with preexisting neuropathy >/= grade 2.

2. Patients may not be receiving any other investigational agents.

3. Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse

4. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to CT-2103, gemcitabine or other agents used in study. History of typical
paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.

5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study.

7. Previous history of stem cell transplantation.

8. History of central nervous system metastases.

9. While there is no strict exclusion based upon previous number of therapies, patients
who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood
count (WBC) growth factor support during their most recent chemotherapy prior to
enrollment are excluded. Exceptions to this would include patients who received
growth factor support as mandated by a clinical study, and/or patients who have been
off all chemotherapy for at least 6 months.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD) of CT-2103

Outcome Description:

MTD defined as the level of CT-2103 at which 2 out of 6 patients had dose limiting toxicity (DLT) where the primary DLT events of CT-2103 are uncomplicated neutropenia, febrile neutropenia, and/or grade 3 neuropathy. Assessments during the first cycle of therapy, where cycle is 21 days.

Outcome Time Frame:

21 days

Safety Issue:


Principal Investigator

Marjorie Green, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 2005

Completion Date:

October 2012

Related Keywords:

  • Metastatic Breast Cancer
  • Breast Cancer
  • Metastatic Breast Cancer
  • Breast Cancer
  • CT-2103
  • Gemcitabine
  • Xyotax
  • Gemzar
  • Breast Neoplasms



UT MD Anderson Cancer Center Houston, Texas  77030